Fixx Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from bleeding disorders. One of Fixx's main areas of focus is Hemophilia.
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. Blood contains many proteins called clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factor in the blood. The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems.
What is Gene Editing?
Genome editing (also called gene editing) allows scientists the ability to change DNA. The first genome editing technologies were developed in the late 1900s. More recently, a new genome editing tool called CRISPR, invented in 2009, has made it easier than ever to edit DNA. CRISPR is simpler, faster, cheaper, and more accurate than older genome editing methods. Like Fixx, many scientists who perform genome editing now use CRISPR.
Who Founded Fixx?
Fixx Pharmaceuticals was founded by serial entrepreneur Jesse John Francis Clark.
Clark was born with severe Hemophilia A, a Factor VIII deficiency. Clark also has two daughters who are Hemophilia carriers.
Clark has studied gene editing through Harvard University.